NCT02423343 2021-09-09
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01220271 2017-02-16
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Eli Lilly and Company
Phase 1/2 Completed